Using feedback letters to influence the use of antiulcer agents in a Medicaid program.
OBJECTIVE
To determine the impact of printed patient-specific feedback regarding potential misprescribing of antiulcer agents (AUAs). Measures of impact included improvements in patients' dispensing profiles, assessed according to predetermined criteria, and decreases in cost and quantity of AUAs dispensed.


METHODS
Controlled study. After evaluation for compliance with predetermined criteria, prescribers identified as having one or two patient profiles with potential errors were assigned alternatively to control or experimental groups. An intervention was mailed to the experimental group.


METHODS
Outpatient setting in the New Mexico Medicaid population.


METHODS
Patients and prescribers identified as having potential misprescribing of AUAs.


METHODS
The intervention consisted of a cover letter describing the purpose of the drug utilization review program, an educational fact sheet regarding prescribing AUAs, patient profiles with potential misprescribing, and physician response forms.


RESULTS
There were greater improvements in dispensing to patients in the intervention group (chi2, p <.001). Significant odds ratios for the intervention group were 2.29 for AUAs discontinued, 1.98 for all improvements combined, 13.13 for improvement in listing of proper diagnosis for AUAs, and 2.84 for appropriate indication when prescribing the higher acute daily dosage. Using data from 3 months before and after the intervention, we found greater decreases in mean monthly costs (p =.044) and mean monthly quantity of AUAs dispensed (p =.049) in the intervention group.


CONCLUSIONS
This intervention significantly decreased AUA dispensing to patients whose prescribers were mailed the patient-specific feedback intervention.
Raisch
D W
DW
Veterans Affairs Cooperative Studies Program, Clinical Research Pharmacy Coordinating Center, and the University of New Mexico College of Pharmacy, Albuquerque, NM 87106, USA.
Sleath
B L
BL
D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D015709:Correspondence as Topic; D017723:Drug Utilization Review; D005246:Feedback; D006266:Health Education; D006801:Humans; D008484:Medicaid / Q000592:standards*; D009516:New Mexico; D010818:Practice Patterns, Physicians'; D011785:Quality Assurance, Health Care; D014481:United States
D000897:Anti-Ulcer Agents